KANE BIOTECH

WITH COACTIV+™ TECHNOLOGY

revyve® ANTIMICROBIAL WOUND GEL | XSONX™ HEAL WOUNDS BETTER

Triple Action Innovation

Changing The Paradigm of Wound Care

revyve™ Antimicrobial Wound Gel is changing the paradigm of wound care as the only product on the market that combines the unique triple-action formulation of a powerful antimicrobial, our patented coactiv+™ antibiofilm technology and a high-concentration surfactant, with our dynamic smartFILL™ gelling system, for optimal wound healing.

1. **Kane's patented coactiv+™ antibiofilm technology**
   Specifically formulated to disrupt biofilm structures (1, 2), inhibit excessive protease levels(3), and maintain mildly acidic wound pH, ideal for healing. (4)
2. **PHMB Antimicrobial**
   Provides lasting antimicrobial activity for a minimum of 7 days (5, 6), supports healing without inhibiting epithelialization (7-9), is biocompatible and has a high therapeutic index (8, 9) with no antimicrobial resistance development. (9)
3. **Highly-Concentrated Surfactant Gel**
   Aids autolytic debridement, naturally removing dead tissue (10, 11), maintains an optimal moist wound environment without causing maceration (12), and form-fits and strongly adheres to wounds. (5, 6, 13)

Innovative Vibrational Debridement Technology:

XSONX® Wound Hygiene System is a battery powered wound therapy system with innovative Vibrational Debridement Technology (VDT) to powerfully clean and debride wounds. XSONX® helps speed up the wound healing process by removing exudates, devitalized tissue, bacterial biofilm, slough, fibrin, and excised or fragmented tissue and offers:

- less pain and anxiety for the patient
- ease of use for practitioners
- reduced procedural time and cost savings
- precise and uniform debridement
- superior wound bed prep prior to tissue grafting
- significant reduction in bioburden especially when used in combination with revyve™ Antimicrobial Wound Gel.

Successful Use of a Novel Debridement Tool and Gel in the Management of Chronic, Painful Venous Leg Ulcers: A Case Study

Rohan Pointer, MD; Iris Noland, MD; Miloslav Sailer, PhD

Kane Biotech Inc,
Winnipeg, Manitoba, Canada
Contact: msailer@kanebiotech.com

Case History

A 62 year-old woman with diabetes, obesity and chronic fibrotic phlebolymphedema of her lower limbs suffered from recurring venous ulcers on her legs over the last 20 years

Clinical Situation

In March of 2023, she developed circumferential, painful, venous ulcers on her lower left leg. These wounds were colonized with ciprofloxacin-resistant *Pseudomonas aeruginosa* and did not heal with standard management. The pain impaired her daily activities.

Actions Taken

A 2-month course of treatment was initiated on January 8th, 2025 with weekly mechanical debridement using XSONX® followed by application of revyve™ Antimicrobial Wound Gel.

Outcomes

The patient had a complete resolution of wound pain after 6 weeks of the treatment. It was well tolerated with no adverse effects. There was a significant reduction in the surface area of all wounds.

Implication for Practice

XSONX® and revyve™ seem to offer a promising alternative for patients with hard-to-heal venous ulcers, including those colonized by antimicrobial-resistant bacteria.

Posterior Leg:


January 13, 2025


February 28, 2025


March 13, 2025

Lateral Leg:


January 13, 2025


February 28, 2025


March 13, 2025

Lateral Leg:


January 13, 2025


February 28, 2025


March 13, 2025

Dynamic smartFILL™ Technology



References

(1). Finnegan S, Percival SL. EDTA: An Antimicrobial and Antibiofilm Agent for Use in Wound Care. Adv Wound Care (New Rochelle). 2015 Jul 1;4(7):415–21. (2). Gawande G, LoVetri K, Yakandawala N, Froelich G, Madhyastha S. Antimicrobial-antibiofilm compositions and methods of use thereof [Internet]. Winnipeg, MB: US9980497B2. 2018. Available from: https://patents.google.com/patent/US9980497B2 (3). Visvalingam J, Yakandawala N, Regmi S, Lee SP, Sailer M. A Chelation approach to biofilm and metalloprotease problem in chronic Wounds. In: he Symposium on Advanced Wound Care Spring, National Habor, BD, USA.; 2023. (4). Rodgers A, Watret L. The role of pH modulation in wound bed preparation. The Diabetic Foot. 2005;8(3):154–7. (5). Visvalingam J, Regmi S, Lee SP, Edwards M, Abdo R, Schultz G. A thermo-reversible hydrogel against chronic, burn and combat wound associated pathogens, and its application to colonized wounds. In: The Symposium on Advanced Wound Care Spring, Orlando, FL, USA; 2024. (6). Sailer M, Visvalingam J, Regmi S, Muzaleva A, Schultz G. A novel thermo-reversible antimicrobial hydrogel spray with effective antibiofilm properties to treat complex combat wounds. MHSRS, in Kissimmee FL, USA; 2024. (7). Hübner NO, Kramer A. Review on the Efficacy, Safety and Clinical Applications of Polihexanide, a Modern Wound Antiseptic. Skin Pharmacol Physiol. 2010;23(Suppl. 1):17–27. (8). Gray D, Barrett S, Battacharyya M, Butcher M, Enoch S, Fumerola S, et al. PHMB and its potential contribution to wound management. Wounds UK. 2010;6(2):40–6. (9). Rippon MG, Rogers AA, Ousey K. Polyhexamethylene biguanide and its antimicrobial role in wound healing: a narrative review. J Wound Care. 2023 Jan 2;32(1):5–20. (10). Percival SL, Chen R, Mayer D, Salisbury A. Mode of action of poloxamer-based surfactants in wound care and efficacy on biofilms. Int Wound J. 2018 Jun 5;15(5):749–55. (11). Percival SL, Mayer D, Kirsner RS, Schultz G, Weir D, Roy S, et al. Surfactants: Role in biofilm management and cellular behaviour. International Wound Journal. 2019 Jun;16(3):753–60. (12). Visvalingam J, Yakandawala N, Regmi S, Sharma P, Sailer M. Anti-biofilm and anti-metalloprotease activity of a novel wound gel. In: The Symposium on Advanced Wound Care Fall. Las Vegas, NV, USA; 2022. (13). Visvalingam J, Sailer M, Edwards M, Schultz G. A Novel Thermo-Reversible Antimicrobial Hydrogel Spray to Treat Complex Combat Wounds. In: MTEC Annual Meeting. Baltimore, MD, USA.; 2024.